Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

the 31 patients with stable disease or better, one

patient had a complete response and four patients had partial

responses (two unconfirmed).

-- SNS-595 has been generally well tolerated in this trial, with a low

rate of febrile neutropenia or other Grade 3/4 adverse events and

manageable Grade 1/2 nausea or vomiting. Based on the drug's

observed safety profile and indications of clinical activity,

Sunesis amended the protocol to explore a higher dose of SNS-595 in

this trial. Enrollment has begun at a dose of 60 mg/m2 over twenty-

eight days, and Sunesis anticipates enrolling approximately 30

patients at this dose in the third quarter of this year.

-- Data from this trial has been accepted for presentation at the 44th

ASCO Annual Meeting.

-- Sunesis updated the results from the company's Phase 1 clinical trial

of single-agent SNS-595 in patients with relapsed or refractory acute

leukemias, which had previously been reported at the 49th Annual

Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia

in December 2007. Since the ASH presentation, an additional patient in

this trial has achieved a complete remission.

-- Twelve of 30 patients (43 percent) who received doses of SNS-595 of

50 mg/m2 or greater on a weekly dose schedule have now achieved bone

marrow blast reductions to less than five percent, and five of these

12 patients achieved either complete remission, complete remission

without platelet recovery or complete remission with incomplete

recovery of normal hematopoietic blood elements.

-- SNS-595 was generally well tolerated in this trial, with a

dose-limiting toxicity of reversible Grade 3/4 oral mucositis.

-- Based on these promising results, Sunesis
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 ... Paris en décembre 2011, l,étude ...   », qui compare   l es ...   sorafénib dans le carcinome hépatocellulaire avancé, a ... du foie avancé   ; les résultats sont ...
(Date:3/3/2015)... 03, 2015 Experts and industry insiders ... one event: the Alltech REBELation exploring innovation, inspiration and ... Now in its 31st year, Alltech’s annual international conference ... and the opportunity to join the REBELation at an ... 11:59 p.m. EST, at which point the standard early ...
(Date:3/3/2015)... -- Adaptive Biotechnologies announced today that Chad Cohen ... Director as Chair of the Audit Committee. ... all finance, treasury and accounting functions. Since joining Zillow ... and accounting functions, and led the finance organization through ... was named Puget Sound Business Journal,s CFO of the ...
(Date:3/3/2015)... Calif. (PRWEB) March 03, 2015 The ... management excellence were honored by the Global Supply ... event which took place on Wednesday, February 25th, 2015, ... The GSCRC was formed to bring together supply chain ... leaders to advance the professional discipline through opportunities to ...
Breaking Biology Technology:Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4
... Aug. 16, 2011 Quanterix Corporation, a company ... based on its revolutionary Si ngle ... STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX), ... of automated analyzer systems, today announced an agreement ...
... The Society of Interventional Radiology Foundation launched a ... the future of the specialty with its announcement ... student conducting preclinical research in interventional radiology during ... prestigious Medical Research Fellows Program. (Logo: ...
... 2011 PharmAthene, Inc. (NYSE Amex: PIP ... and chemical threats, announced today that the Company has ... of Defense (DoD) Broad Agency Announcement for studies directed ... the bioproduction of its nerve agent medical countermeasure program. ...
Cached Biology Technology:Quanterix and STRATEC Announce Strategic Partnership 2Quanterix and STRATEC Announce Strategic Partnership 3Society of Interventional Radiology Foundation Funds Howard Hughes Medical Institute Award 2Society of Interventional Radiology Foundation Funds Howard Hughes Medical Institute Award 3Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program 2Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program 3Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program 4
(Date:2/5/2015)... 28, 2015 New Market Research ... Segment Forecasts To 2020 has Been Added to GrandViewReseach.com ... is expected to reach USD 5.10 billion by 2020, ... Inc. IR cameras help identify the site of tissue ... witness surging demand in medical imaging applications. They have ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Novartis announced today that scientists at the Novartis ... from the Genomics Institute of the Novartis Research Foundation ... The Scripps Research Institute have discovered a novel compound ... drug resistant malaria. Major support for the project was ...
... California Institute of Technology (Caltech) have devised a new ... visualize the structure of molecules. The technique, which was ... water coats surfaces at room temperature, can also be ... molecules, including antibodies and other biomolecules. A paper ...
... of the first implantable artificial kidney, in a development ... The device, which would include thousands of microscopic ... metabolic and water-balancing roles of a real kidney, is ... and physicians nationwide, led by Shuvo Roy, PhD, in ...
Cached Biology News:Novartis and collaborators discover novel antimalarial drug candidate 2Novartis and collaborators discover novel antimalarial drug candidate 3Caltech chemists develop simple technique to visualize atomic-scale structures 2Caltech chemists develop simple technique to visualize atomic-scale structures 3UCSF unveils model for implantable artificial kidney to replace dialysis 2UCSF unveils model for implantable artificial kidney to replace dialysis 3